FrancophonIA/ELRC3.0 huggingface dataset:
English: DUTREBIS should be used with caution in patients who have had myopathy or rhabdomyolysis in the past or have any predisposing issues including other medicinal products associated with these conditions (see section 4.8).
Slovenian: Zdravilo DUTREBIS je treba previdno uporabljati pri bolnikih, ki so že kdaj imeli miopatijo ali rabdomiolizo, in pri bolnikih, ki imajo kateri koli predispozicijski dejavnik, vključno z zdravljenjem z drugimi zdravili, povezanimi z njima (glejte poglavje 4.8).
English: Durable outcomes (Week 48 and Week 96) for patients on the recommended dose raltegravir 400 mg twice daily from the pooled studies BENCHMRK 1 and BENCHMRK 2 are shown in Table 2.
Slovenian: Preglednica 2 prikazuje dolgotrajne izide (po 48 in 96 tednih) pri bolnikih, ki so prejemali priporočeni odmerek 400 mg raltegravirja dvakrat na dan iz združenih študij BENCHMRK 1 in BENCHMRK 2.
English: In faeces, only raltegravir was present, most of which is likely to be derived from hydrolysis of raltegravir-glucuronide secreted in bile as observed in preclinical species.
Slovenian: V blatu je bil prisoten le raltegravir, ki je v največji meri verjetno nastal s hidrolizo raltegravirjevega glukuronida in se izločil z žolčem, kot so ugotovili v predkliničnih raziskavah.
English: The clinical significance of these findings is
Slovenian: Klinični pomen takšnih izsledkov
English: In HIV-infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Slovenian: Pri bolnikih, okuženih s HIV, ki so v času uvedbe kombiniranega protiretrovirusnega zdravljenja imunsko zelo oslabeli, se lahko pojavi vnetna reakcija na asimptomatske ali rezidualne oportunistične okužbe.
English: Patients had prior exposure to a median of 12 anti-retrovirals for a median of 10 years.
Slovenian: Bolniki so se predhodno zdravili z 12 protiretrovirusnimi zdravili (mediana vrednost) in zdravljenje je trajalo 10 let (mediana vrednost).
English: Raltegravir 400 mg twice daily (N = 281)
Slovenian: 240 tednov raltegravir 400 mg dvakrat na dan (N = 281)
English: Raltegravir at concentrations of 31  20 nM resulted in 95 % inhibition (IC95) of HIV-1 replication (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures infected with the cell-line adapted HIV-1 variant H9IIIB.
Slovenian: V celičnih kulturah humanih T-limfoidnih celic, okuženih z varianto virusa HIV-1 H9IIIB, prilagojeno za celično linijo, je raltegravir v koncentracijah 31  20 nM povzročil 95 % zaviranje (IC95) replikacije virusa HIV-1 (v primerjavi z netretiranimi, z virusom okuženimi kulturami).
English: • infection of the hair roots; influenza; skin infection due to virus; upper respiratory tract infection(such as inflammation of the nasal cavity or sinuses located around the nose; common cold); infection in the lymph node (gland in the neck, armpit, or groin)
Slovenian: • okužba korenin las ali dlak, gripa, virusna okužba kože, okužba zgornjih dihal (kot sta vnetje nosne votline ali sinusov, ki se nahajajo v bližini nosu, običajen prehlad), okužba bezgavk (žleze na vratu, pod pazduho in v dimljah)
English: DUTREBIS is used to treat HIV (Human Immunodeficiency Virus).
Slovenian: Zdravilo DUTREBIS uporabljamo za zdravljenje okužbe z virusom HIV (virusom humane imunske pomanjkljivosti).
English: One patient experienced drug related laboratory abnormalities, Grade 4 AST and Grade 3 ALT, which
Slovenian: Pri enem bolniku so se pojavile z zdravilom povezane nenormalne laboratorijske vrednosti AST (4. stopnje) in ALT (3. stopnje), ki so bile ocenjene kot resne.
English: Co-administration of DUTREBIS with medicinal products that are known to be potent UGT1A1 inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir.
Slovenian: Sočasna uporaba zdravila DUTREBIS z zdravili, ki močno zavirajo UGT1A1 (npr. atazanavir), lahko poveča koncentracijo raltegravirja v plazmi.
English: The most frequently reported adverse reactions during treatment with raltegravir were headache and nausea.
Slovenian: Med zdravljenjem z raltegravirjem so najpogosteje poročali o glavobolu in navzeji.
English: This is because it is very important not to be without the medicine, even for a short time.
Slovenian: To je zelo pomembno, saj ne smete biti brez zdravila, tudi kratek čas ne. Že med kratko prekinitvijo jemanja zdravila se lahko poveča količina virusa v krvi.
English: No effect on fertility was seen in male and female rats at doses of raltegravir up to 600 mg/kg/day which resulted in 3-fold exposure above the exposure at the recommended human dose.
Slovenian: Pri samcih in samicah podgan med uporabo odmerkov raltegravirja do 600 mg/kg/dan, ki so povzročili 3-krat večjo izpostavljenost, kot je dosežena s priporočenim odmerkom za človeka, niso opazili vpliva na plodnost.
English: If creatinine clearance decreases to <50 ml/min, DUTREBIS should be switched to a regimen of the individual components (lamivudine and raltegravir) (see section 4.2).
Slovenian: Če se očistek kreatinina zmanjša na < 50 ml/min, je treba z zdravila DUTREBIS preiti na zdravljenje s posameznima učinkovinama (lamivudinom in raltegravirjem) (glejte poglavje 4.2).
English: Concomitant use of
Slovenian: Navodilo za uporabo
English: Two components, namely raltegravir and raltegravir-glucuronide, were detected in urine and accounted for approximately 9 and 23 % of the dose, respectively.
Slovenian: V urinu so odkrili dve spojini: raltegravir in raltegravirjev glukuronid; raltegravir je predstavljal približno 9 % odmerka, raltegravirjev glukuronid pa 23 % odmerka.
English: Co-administration of DUTREBIS with antacids containing divalent metal cations may reduce raltegravir absorption by chelation, resulting in a decrease of raltegravir plasma levels.
Slovenian: Sočasna uporaba zdravila DUTREBIS z antacidi, ki vsebujejo dvovalentne kovinske katione, lahko zaradi kelacije zmanjša absorpcijo raltegravirja, kar vodi do zmanjšane koncentracije raltegravirja v plazmi.
English: BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled studies) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. placebo in a combination with optimized background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 medicinal product in each of 3 classes (NRTIs, NNRTIs, PIs) of anti-retroviral therapies.
Slovenian: Študiji BENCHMRK 1 in BENCHMRK 2 (multicentrični, randomizirani, dvojno slepi, s placebom nadzorovani študiji) sta ovrednotili varnost in protiretrovirusno delovanje 400 mg raltegravirja dvakrat na dan v primerjavi s placebom v kombinaciji z optimiziranim osnovnim zdravljenjem (OBT - optimized background therapy) pri bolnikih, okuženih z virusom HIV, starih 16 let ali več in z dokazano odpornostjo na vsaj 1 zdravilo iz vsake od 3 skupin protiretrovirusnih zdravil (NRTI, NNRTI in PI).
English: In both studies at Week 24, suppression of HIV RNA to less than 50 copies/ml was maintained in 84.4 % of the raltegravir group versus 90.6 % of the lopinavir (+) ritonavir group, (Non-completers = Failure).
Slovenian: HIV RNA na manj kot 50 kopij/ml ohranila pri 84,4 % bolnikov v skupini, ki je prejemala raltegravir, in pri 90,6 % bolnikov v skupini, ki je prejemala lopinavir (+) ritonavir (z uporabo metode nedokončanje = neuspeh).
English: DUTREBIS should not be used in children below 6 years of age or in patients weighing less than 30 kg due to weight based dosing requirements in this patient population (see section 5.2).
Slovenian: Zdravila DUTREBIS se ne sme uporabljati pri otrocih, mlajših od 6 let, ali pri bolnikih s telesno maso manj kot 30 kg, ker je treba odmerek v tej populaciji bolnikov določiti glede na telesno maso (glejte
English: The exposure-adjusted rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100 patient-years (PYR), respectively; and for drug-related rash were 2.4, 1.1, and 2.3 per 100 PYR, respectively.
Slovenian: Delež izpuščaja (ne glede na vzrok), prilagojen glede na izpostavljenost, je bil 10,9 oz. 4,2 oz. 3,8 na 100 bolnikov-let; delež z zdravilom povezanega izpuščaja pa 2,4 oz. 1,1 oz. 2,3 na 100 bolnikov-let.
English: CART has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump).
Slovenian: Kombinirano protiretrovirusno zdravljenje je bilo pri bolnikih, okuženih s HIV, povezano s prerazporeditvijo telesnega maščevja (lipodistrofijo), ki vključuje izgubo podkožnega maščevja periferno in na obrazu, povečanje itraabdominalnega in visceralnega maščevja, hipertrofijo dojk in dorzocervikalno kopičenje maščevja (bivolja grba).
English: Ethinyl Estradiol AUC  2 % Ethinyl Estradiol Cmax ↑ 6 % Norelgestromin AUC ↑ 14 % Norelgestromin Cmax ↑ 29 %
Slovenian: AUC etinilestradiola  2 % Cmax etinilestradiola ↑ 6 % AUC norelgestromina ↑ 14 % Cmax norelgestromina ↑ 29 %
English: Lamivudine is predominately cleared unchanged by renal excretion.
Slovenian: Lamivudin se v glavnem izloča skozi ledvice v nespremenjeni obliki.
English: Raltegravir was not teratogenic in developmental toxicity studies in rats and rabbits.
Slovenian: Raltegravir v študijah škodljivih vplivov na razvoj pri podganah in kuncih ni bil teratogen.
English: Myopathy and rhabdomyolysis
Slovenian: Miopatija in rabdomioliza
English: Myopathy and rhabdomyolysis have been reported.
Slovenian: Poročali so o miopatiji in rabdomiolizi.
English: To monitor maternal-foetal outcomes in patients inadvertently administered DUTREBIS while pregnant, an Anti-retroviral Pregnancy Registry has been established.
Slovenian: Register nosečnic, med nosečnostjo zdravljenih s protiretrovirusnimi zdravili Za spremljanje izidov nosečnosti (izidov za mater in plod) pri bolnicah, ki so med nosečnostjo pomotoma jemale zdravilo DUTREBIS, je bil vzpostavljen Register nosečnic, med nosečnostjo zdravljenih s protiretrovirusnimi zdravili.
English: Tell your doctor, pharmacist or nurse immediately if you notice any symptoms of infection, such
Slovenian: Nemudoma obvestite zdravnika, farmacevta ali medicinsko sestro, če opazite kateri koli simptom okužbe, na primer:
English: Remember that DUTREBIS is not a cure for HIV infection.
Slovenian: Ne pozabite, da zdravilo DUTREBIS ne ozdravi okužbe z virusom HIV.
English: Table 3 Efficacy Outcome at Weeks 48 and 240
Slovenian: Izid učinkovitosti v 48. in 240. tednu zdravljenja
English: trimethoprim /sulfamethoxazole /raltegravir
Slovenian: atazanavir/ritonavir /raltegravir
English: DUTREBIS is not a cure for HIV infection.
Slovenian: Zdravilo DUTREBIS ne ozdravi okužbe z virusom HIV.
English: DUTREBIS is not recommended for use as monotherapy.
Slovenian: Zdravila DUTREBIS ni priporočljivo uporabljati samostojno (v obliki monoterapije).
English: Investigations common atypical lymphocytes, elevations in liver enzymes (AST, ALT), blood triglycerides increased, lipase increased, blood pancreatic amylase uncommon absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
Slovenian: netipični limfociti, zvišani jetrni encimi (AST, ALT), zvišani trigliceridi v krvi, zvišane lipaze, zvišana pankreatična amilaza v krvi zmanjšano absolutno število nevtrofilcev, zvišana alkalna fosfataza, znižani albumini v krvi, zvišana amilaza v krvi, zvišan bilirubin v krvi, zvišan holesterol v krvi, zvišan kreatinin v krvi, zvišana glukoza v krvi, zvišana sečnina v krvi, zvišana kreatin fosfokinaza, zvišana glukoza v krvi na tešče, prisotnost glukoze v urinu, zvišani lipoproteini velike gostote (HDL), povišano internacionalno normalizirano razmerje, zvišani lipoproteini majhne gostote (LDL), zmanjšano število trombocitov, pozitiven izvid eritrocitov v urinu, povečan obseg pasu, povečanje telesne mase, zmanjšano število belih zapleti postopkov
English: Interactions between the components of DUTREBIS and co-administered medicinal products are listed
Slovenian: Medsebojno delovanje med učinkovinama zdravila DUTREBIS in sočasno uporabljenimi zdravili so
English: Lamivudine demonstrates low cytotoxicity to peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage cell lines, and to a variety of bone marrow progenitor cells in vitro.
Slovenian: Citotoksičnost lamivudina za limfocite iz periferne krvi, dozorele celične linije limfocitov in monocitov-makrofagov in različne progenitorske celice kostnega mozga in vitro je majhna.
English: The types and rates of specific cancers were those expected in a highly immunodeficient population.
Slovenian: Specifična rakava obolenja so po vrsti in deležu ustrezala pričakovanim pri bolnikih s hudo imunsko pomanjkljivostjo.
English: The safety profile observed in patients who used atazanavir and / or tenofovir was generally similar to the safety profile of patients who did not use these agents.
Slovenian: Pri bolnikih, ki so uporabljali atazanavir in/ali tenofovir, je bil varnostni profil na splošno podoben kot pri bolnikih, ki niso uporabljali teh dveh zdravil, zato odmerka zdravila DUTREBIS ni treba prilagoditi.
English: Raltegravir is also available in a chewable tablet formulation for children weighing at least 11 kg and in granules for oral suspension formulation for infants and toddlers from 4 weeks of age and weighing at least 3 kg to less than 20 kg.
Slovenian: Raltegravir je na voljo tudi v obliki žvečljivih tablet za uporabo pri otrocih s telesno maso vsaj 11 kg in v obliki zrnc za peroralno suspenzijo za uporabo pri dojenčkih in malčkih, od 4. tedna starosti, s telesno maso najmanj 3 kg in manj kot 20 kg. Za dodatne informacije glede odmerjanja žvečljivih tablet in zrnc za peroralno suspenzijo glejte ustrezen povzetek glavnih značilnosti zdravila.
English: Patient demographics (gender, age and race) and baseline characteristics were comparable between the groups receiving raltegravir 400 mg twice daily and placebo.
Slovenian: Demografske (spol, starost in rasa) in izhodiščne značilnosti so bile med prejemniki 400 mg raltegravirja dvakrat na dan in prejemniki placeba primerljive.
English: High density polyethylene (HDPE) bottle with a child-resistant closure (HDPE) with foil induction seal
Slovenian: Plastenka iz polietilena visoke gostote (HDPE) z zaporko, varno za otroke (HDPE), z zaščitno folijo.
English: Nucleoside and nucleotide reverse transcriptase inhibitors have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Slovenian: In vitro in in vivo je bilo dokazano, da nukleozidni in nukleotidni zaviralci reverzne transkriptaze v različni meri okvarijo mitohondrije.
English: Co-administration of other medicinal products
Slovenian: Sočasna uporaba z drugimi zdravili
English: • loss of memory; pain in the hand due to nerve compression; disturbance in attention; dizziness with rapid changes in posture; abnormal taste; increased sleepiness; lack of energy; forgetfulness; migraine headache; reduced sense of touch, numbness or weakness of the arms and/or legs; tingling; sleepiness; tension headache; tremors; poor quality sleep
Slovenian: • izguba spomina, bolečine v dlaneh zaradi pritiska na živec, motnje pozornosti, omotica po hitri spremembi položaja telesa, motnje okušanja, večja zaspanost, pomanjkanje energije, pozabljivost, migrenski glavobol, zmanjšana občutljivost za dotik, omrtvičenost ali šibkost rok in/ali nog, mravljinčenje, zaspanost, tenzijski glavobol, tresenje, slaba
English: Delay in stopping DUTREBIS treatment or other suspect agents after the onset of severe rash may result in a life-threatening reaction.
Slovenian: Odlašanje s prenehanjem zdravljenja z zdravilom DUTREBIS ali drugimi zadevnimi zdravili po pojavu hudega izpuščaja lahko povzroči
English: • back pain; pain in bone/muscle; muscle tenderness or weakness; neck pain; pain in arms or legs; inflammation of the tendons; decrease in the amount of minerals in the bone
Slovenian: • bolečine v hrbtu, bolečine v kosteh/mišicah, občutljive ali šibke mišice, bolečine v vratu, bolečine v rokah ali nogah, vnetje tetiv, zmanjšana količina mineralov v kosteh
English: No dosage adjustment is necessary for DUTREBIS based on gender, race, or BMI.
Slovenian: Odmerka zdravila DUTREBIS ni treba prilagoditi glede na spol, raso ali ITM.
English: Cases of lactic acidosis, sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues (see section 4.4).
Slovenian: Med uporabo nukleozidnih analogov so poročali o primerih laktacidoze (v nekaterih primerih s smrtnim izidom), po navadi skupaj s hudo hepatomegalijo in steatozo jeter (glejte poglavje 4.4).
English: Lamivudine has not been specifically investigated in HIV patients co-infected with HBV.
Slovenian: Učinkovitosti lamivudina pri bolnikih z virusom HIV, ki so sočasno okuženi z virusom HBV, niso posebej preučevali.
English: *The adverse reaction data was collected based on each individual component of DUTREBIS.
Slovenian: Podatki o neželenih učinkih so zbrani na podlagi vsake od obeh posameznih učinkovin zdravila DUTREBIS.
English: • high doses of co-trimoxazole - used to treat infections.
Slovenian: • velike odmerke kotrimoksazola - uporablja se za zdravljenje okužb
English: The pharmacokinetic properties of lamivudine have been determined in adults with impaired hepatic function.
Slovenian: Farmakokinetične lastnosti lamivudina so proučili pri odraslih z okvarjenim delovanjem jeter.
English: These results indicate that raltegravir is not an inducer or inhibitor of CYP3A4, and raltegravir is thus not anticipated to affect the pharmacokinetics of medicinal products which are CYP3A4 substrates.
Slovenian: Ti rezultati kažejo, da raltegravir ne inducira in ne zavira CYP3A4.
English: Your doctor may decide to change your dose by using the medicines in DUTREBIS separately, if you are taking rifampicin.
Slovenian: Zdravnik se lahko odloči in vam odmerek spremeni, in sicer tako, da boste ločeno jemali vsako od obeh učinkovin, ki ju vsebuje zdravilo DUTREBIS.
English: • muscle pain and discomfort, joint pain
Slovenian: • bolečine in nelagodje v mišicah, bolečine v sklepih
English: Co-administration of DUTREBIS with aluminium and/or magnesium containing antacids is not recommended.
Slovenian: Sočasna uporaba zdravila DUTREBIS z antacidi, ki vsebujejo aluminij in/ali magnezij, ni priporočljiva.
English: The extent to which raltegravir may be dialysable is unknown.
Slovenian: Obseg izločanja raltegravirja s hemodializo ni znan.
English: Rash considered by the investigator to be drug-related occurred at similar rates.
Slovenian: Pojavnost izpuščaja, ki je bil po oceni raziskovalca vzročno povezan z zdravilom, je bila podobna.
English: Administration of co-trimoxazole with lamivudine in patients with renal impairment should be carefully assessed.
Slovenian: Pri bolnikih z okvaro ledvic je treba uporabo kotrimoksazola z lamivudinom skrbno oceniti.
English: • The active substances are lamivudine and raltegravir.
Slovenian: • Zdravilni učinkovini sta lamivudin in raltegravir.
English: Results 48 week and 96 week analyses
Slovenian: Izid učinkovitosti v 48. in 96. tednu zdravljenja
English: • lactic acidosis - signs include deep, fast, difficult breathing, feeling drowsy, numb or weak arms or legs, feeling or being sick (nausea or vomiting), stomach pain
Slovenian: • laktacidoza - med znaki so globoko, hitro, težko dihanje, zaspanost, omrtvičenost ali šibkost rok ali nog, siljenje na bruhanje ali bruhanje, bolečine v trebuhu.
English: At 240-weeks, in treatment-naïve patients, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 22 %, 44 % and 17 %, respectively, of co-infected subjects treated with raltegravir as compared to 13 %, 13 % and 5 % of all other subjects treated with raltegravir.
Slovenian: V 240. tednu so se pri predhodno nezdravljenih bolnikih s sočasno okužbo, ki so se zdravili z raltegravirjem, pojavila odstopanja od normalnih laboratorijskih vrednosti 2. stopnje ali več, kar predstavlja poslabšanje stopnje v primerjavi z izhodiščno vrednostjo AST pri 22 % bolnikov, ALT pri 44 % bolnikov in skupnega bilirubina pri 17 % bolnikov, v primerjavi z vsemi ostalimi osebami, ki so prejemale raltegravir, pri katerih so se odstopanja vrednosti AST pojavila pri 13 % bolnikov, ALT pri 13 % bolnikov in skupnega bilirubina pri 5 % bolnikov.
English: Co-administration of rifampicin with DUTREBIS is not recommended.
Slovenian: Sočasna uporaba rifampicina z zdravilom DUTREBIS ni priporočljiva.
English: No evidence of mutagenicity or genotoxicity was observed in in vitro microbial mutagenesis (Ames) tests, in vitro alkaline elution assays for DNA breakage and in vitro and in vivo chromosomal aberration studies conducted with raltegravir.
Slovenian: Z raltegravirjem pri testih mutageneze na mikrobih (Amesov test) in vitro, preizkusih alkalne elucije za ugotavljanje poškodb DNA in vitro in študijah kromosomskih aberacij in vitro ter in vivo niso odkrili znakov mutagenosti ali genotoksičnosti.
English: Some people taking DUTREBIS or other antiretroviral medicines may have other effects show up
Slovenian: Pri nekaterih bolnikih, ki jemljejo zdravilo DUTREBIS ali druga protiretrovirusna zdravila, se lahko pojavijo tudi spremembe izvidov preiskav krvi:
English: Do not operate machines, drive or cycle if you feel dizzy after taking this medicine.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Če ste med jemanjem tega zdravila omotični, ne smete upravljati s stroji, voziti ali kolesariti.
English: Each film-coated tablet contains 150 mg of lamivudine and 300 mg of raltegravir (as potassium)
Slovenian: Ena filmsko obložena tableta vsebuje 150 mg lamivudina in 300 mg raltegravirja (v obliki kalijeve
English: raltegravir AUC  55 % raltegravir C12 hr  32 % raltegravir Cmax  52 %
Slovenian: AUC raltegravirja  55 % C12ur raltegravirja  32 % Cmax raltegravirja  52 %
English: Raltegravir is an integrase strand transfer inhibitor active against the Human Immunodeficiency Virus
Slovenian: Raltegravir je zaviralec integraze, ki deluje proti virusu humane imunske pomanjkljivosti (HIV-1).
English: No dose adjustment required for DUTREBIS or tenofovir disoproxil fumarate.
Slovenian: Odmerka zdravila DUTREBIS ali tenofovirjevega dizoproksilfumarata ni treba prilagoditi.
English: Percent HIV-RNA < 50 copies/ml (95 % CI)
Slovenian: 2 in več Odstotek HIV-RNA < 50 kopij/ml (95 % IZ) Vsi bolniki Izhodiščna značilnost
English: Each film-coated tablet contains 150 mg of lamivudine and 300 mg of raltegravir (as potassium).
Slovenian: Ena filmsko obložena tableta vsebuje 150 mg lamivudina in 300 mg raltegravirja (v obliki kalijeve soli).
English: Please refer to the SmPC for the individual components of DUTREBIS for dosing instructions (see section 4.4).
Slovenian: Za navodila o odmerjanju posameznih učinkovin zdravila DUTREBIS, prosimo, glejte povzetka glavnih značilnosti zdravila za ti dve zdravili (glejte poglavje 4.4).
English: Nucleoside/tide reverse transcriptase inhibitors (NRTIs)
Slovenian: Nukleozidni in nukleotidni zaviralci reverzne transkriptaze (NRTI) Medsebojno delovanje ni
English: IT
Slovenian: ES
English: Co-administration of raltegravir with aluminium and magnesium antacids resulted in reduced raltegravir plasma levels.
Slovenian: Sočasna uporaba raltegravirja z aluminijevimi in magnezijevimi antacidi je povzročila zmanjšanje koncentracije raltegravirja v plazmi.
English: • feeling or being sick (nausea or vomiting), diarrhoea, stomach pain
Slovenian: • siljenje na bruhanje ali bruhanje, driska, bolečine v želodcu